Company intelligence / Profile preview

Optas

Ownership: Private
Development stage: Other

Overview

Optas is a pre-clinical stage biotechnology company focused on developing innovative therapies for retinal diseases. The company's lead programs utilize multi-kinase inhibitors designed to target key pathways involved in ocular angiogenesis and inflammation, such as VEGF, PDGF, and FGF. By employing advanced drug delivery technologies, Optas aims to provide long-lasting therapeutic effects and reduce the treatment burden for patients with conditions like wet age-related macular degeneration and diabetic retinopathy. The company is currently advancing its pipeline through rigorous pre-clinical testing to support future clinical development.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Optas.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optas.

Explore the full profile